





























Bone remodelling is regulated by the activity of bone-
forming osteoblasts and bone-resorbing osteoclasts. Both
osteoblasts and osteoclasts are regulated by a variety of
hormones and local factors (Fuller et al. 1998; Lacey et al.
1998; Burgess et al. 1999; Kong et al. 1999). Osteoblasts
stem from mesenchymal stem cells, whereas osteoclasts
arise by the differentiation of osteoclast precursors of
monocyte/macrophage lineage. Osteoblasts and osteoclasts
are required not only for skeletal development, but also for
mineral homeostasis and the normal remodelling of bone
(Raise, 1998). An imbalance between bone formation and
bone resorption causes metabolic bone diseases like
osteopetrosis and osteoporosis (Aubin, 1998). Therefore,
osteoblasts and osteoclasts are known to be closely related
during the process of remodelling (Suda et al. 1995; Tsukii
et al. 1998; Takahashi et al. 1999).
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The Na+–K+–2Cl_ cotransporter (NKCC1) is responsible for ion transport across the secretory and absorptive
epithelia, the regulation of cell volume, and possibly the modulation of cell growth and development. It has
been reported that a variety of cells, including osteoblasts, contain this cotransporter. In this study, the
physiological role of NKCC1 in osteoclastogenesis was exploited in a co-culture system. Bumetanide, a specific
inhibitor of NKCC1, reduced the number of tartrate-resistant acid phosphatase (TRAP)-positive multi-
nucleated cells. In order to investigate the mechanism by which bumetanide inhibits osteoclastogenesis, the
mRNA expressions of the receptor activator of nuclear factor (NF)-kB ligand (RANKL) and osteoprotegerin
(OPG) were analysed by RT-PCR. Exposure of osteoblastic cells to a medium containing 1 mM bumetanide
reduced RANKL mRNA expression induced by 10 nM 1a,25-dihydroxyvitamin D3 (1a,25(OH)2D3, in a dose-
dependent manner. In addition, RANKL expression was also analysed with enzyme-linked immunosorbant
assay (ELISA) using anti-RANKL antibody. The expression of RANKL was decreased with the increase of
bumetanide concentration. In contrast, the expression of OPG mRNA, a novel tumour necrosis factor (TNF)
receptor family member was increased in the presence of bumetanide. These results imply that bumetanide
inhibits osteoclast differentiation by reducing the RANKL/OPG ratio in osteoblastic cells. However, no
significant difference in M-CSF mRNA expression was observed when bumetanide was added. Also, we found
that the phosphorylation of c-Jun NH2-terminal kinase (JNK), which regulates the activity of various
transcriptional factors, was reduced by bumetanide treatment. Conclusively, these findings suggest that
NKCC1 in osteoblasts has a pivotal role in 1a,25(OH)2D3-induced osteoclastogenesis partly via the
phosphorylation of JNK.  Experimental Physiology (2003) 88.5, 569–574.
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Certain kinds of signalling molecules, such as, the receptor
activator of NF-kB ligand (RANKL), osteoprotegerin (OPG)
and macrophage colony-stimulating factor (M-CSF),
expressed by osteoblasts, are involved in osteoclastogenesis
and in osteoclast development. For instance, when osteo-
blasts/stromal cells are stimulated by osteotropic factors
such as parathyroid hormone, RANKL is expressed and
induces the differentiation of osteoclast progenitors by
binding to the receptor activator of NF-kB (RANK; also
known as ODF receptor) (Jimi et al. 1999). In addition,
M-CSF is known to be essential for macrophages to be
transformed into osteoclasts, while OPG, a decoy receptor
of RANKL, is known to participate in the regulation of
osteoclastogenesis (Lacey et al. 1998). Specifically, OPG, as
a member of the tumour necrosis factor receptor (TNFR)
family, inhibits the osteoclastogenesis stimulated by
1a,25(OH)2D3, parathyroid hormone (PTH), or inter-
leukin-11 (IL-11) (Takahashi et al. 1999). Consequently, it
is believed that RANKL, M-CSF and OPG, which are
expressed by osteoblasts, are associated with osteoclasto-
genesis, and that osteoblasts are a major factor in the bone
remodelling process.
With respect to osteoclastogenesis, we have focused on the
function of the osteoblast, because it has been reported
that the Na+–K+–2Cl_ cotransporter (NKCC1) is present in
osteoblasts (Whisenant et al. 1991). Presumably, in osteo-
blasts NKCC1 may be involved in the bone remodelling
process. In general, NKCC1 is present in numerous and
diverse tissues in a wide variety of animal species, and is
associated with the regulation of cell volume, the
maintenance of ionic gradients across the membrane, and
possibly the modulation of cell growth and development
(Haas & Forbush, 1998). Apart from some knowledge of
the general functions of NKCC1 in a variety of cells, there
is no experimental evidence as to whether NKCC1 activity
in osteoblasts is related to osteoclastogenesis. Therefore,
we hypothesized that NKCCl in osteoblasts might concern
osteoclastogenesis with respect to RANKL, OPG and M-CSF
mRNA expression. In this study, we applied an osteoblast/
stromal cell co-culture system to evaluate the effect of
bumetanide, a specific inhibitor of NKCC1, on 1a,25-
(OH)2D3-induced osteoclast formation, mRNA expression
profiles in RANKL, OPG and M-CSF, and changes in total
JNK (t-JNK) and phosphorylated JNK (p-JNK).
METHODS
Materials
Routine cell culture media were obtained from Gibco BRL (Grand
Island, NY, USA). The tartrate-resistant acid phosphatase staining
kit and bumetanide were purchased from Sigma Chemical Co.
(St Louis, MO, USA). Trizol was purchased from Invitrogen
Corp. (Carlsbad, CA, USA), and the ICR mice were from
Samtacho Co. (Seoul, Korea). All other chemicals were of the
highest grade commercially available.
In vitro osteoclast formation assay
The osteoblast formation assay was carried out as previously
reported by Choi et al. (2001). Briefly, the osteoblasts were
isolated from 1- to 2-day-old mice which had been killed by
cervical dislocation. Thirty to fifty calvariae were digested in 10 ml
of an enzyme solution containing 0.2 % collagenase (Wako,
Japan) and 0.1 % dispase (Gibco) for 20 min at 37 °C in a shaking
water bath. The supernatant was discarded and 10 ml of the
enzyme solution was added. After shaking at 37 °C for 20 min,
the supernatant was collected carefully and transferred to a new
tube. This digestion of calvariae by collagenase–dispase was
repeated three times. The collected supernatant (30 ml) was
placed in a centrifuge at 1500 g for 10 min, to collect the
osteoblastic cells. Cells were resuspended in a-minimal essential
medium (MEM) containing 10 % fetal calf serum (FCS) and
cultured to confluence in 10 cm culture dishes at a concentration
of 105 cells per dish. The cells were then detached from the
culture dishes using trypsin-EDTA, suspended in a-MEM with
10 % FCS and used for the co-culture as osteoblastic cells.
Femoral and tibial bone marrow cells, as well as calvariae, were
collected from 4-week-old mice which had been killed by cervical
dislocation. The tibiae and femora were removed and dissected
free of adhering tissues. The bone ends were removed and the
marrow cavities flushed by slowly injecting media at one end
using a 25-gauge needle. The calvariae and bone marrow cells
collected were washed and used in the co-culture.
Mouse calvarial cells (1 w 104 cells well_1) were co-cultured with
bone marrow cells (1 w 105 cells well_1) in a-MEM containing 10 %
fetal calf serum in 48-well plates (Corning). The culture volume
was made up to 400 ml per well with a-MEM supplemented with
10 % fetal calf serum (FCS), in the presence of 1a,25(OH)2D3
(10 nM), with or without bumetanide (1, 10, or 100 mM). All
cultures were maintained at 37 °C in a humidified atmosphere
containing 5 % CO2 in air. After incubation for 4 days, the cells
were subjected to tartrate-resistant acid phosphatase (TRAP, an
osteoclast marker enzyme) staining. In vitro osteoclast formation
assay was repeated four times.
Viability test
The MTT (3-(4,5-dimethylthiazol-2-yl-)-2,5-diphenyltetrazolium
bromide) test is based on the principle that tetrazolium salts are
reduced by mitochondrial enzymes (succinate, dehydrogenase)
and this allows the toxicity of viable cells and the level of cellular
differentiation to be measured. MTT was dissolved in phosphate-
buffered saline (PBS) at 5 mg ml_1 and filtered to remove any
insoluble residue. MTT solution was added directly to the assay
plates. The cells were subsequently incubated for an additional
4 h at 37 °C. The purple formazan crystals that formed were
dissolved in DMSO, and the plates were read on a spectro-
photometer (MRX; Dynatech Laboratories, USA) at 570 nm.
This assay was repeated four times.
RT-PCR
The expressions of RANKL, OPG, M-CSF and b-actin (as a
positive control) were evaluated by RT-PCR using total RNA
isolated from murine osteoblastic cells. Total RNA was isolated
using Trizol. The primers used were: for RANKL (750 bp), 5‚-
ATCAGAAGACAGCACTCACT-3‚ (forward), 5‚-ATCTAG-
GACATCCATGCTAATGTTC-3‚ (reverse); for OPG (636 bp),
5‚-TGAGTGTGAGGAAGGGCGTTAC-3‚ (forward), 5‚-TTC-
CTCGTTCTCTCAATCTC-3‚ (reverse); for M-CSF, 5‚-ATG-
ACAAGGCCTGCGTCCGA-3‚ (forward), 5‚-AAGCTCTGG-
CAGGTGCTCCTG-3‚ (reverse, 395 bp) and 5‚-GCCGCC-
TCCACCTGTAGAACA-3‚ (reverse, 286 bp); and for b-actin
(366 bp), 5‚-GGACTCCTATGGTGGGTGACGAGG-3‚ (forward)
and 5‚-GGGAGAGCATAGCCCTCGTAGAT-3‚ (reverse). PCR
was repeated four times.
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Relative RT-PCR was performed to measure gene expression of
RANKL, OPG and b-actin mRNAs. Polymerase chain reactions
were performed on a Tgradient 96 PCR machine (Whatman
Biometra GmbH, Göttingen, Germany) using ~100 ng of cDNA,
5 pmol of each oligonucleotide primer, 200 mM of each dNTP, 1
unit of Taq polymerase (Applierd Biosystems, CA, USA) and
10 w Taq polymerase buffer in a 50 ml volume. The PCR program
initially started with a 95 °C denaturation for 5 min, followed by
25–38 cycles of 95 °C for 1 min, Ta for 1 min, 72 °C for 1 min (Ta,
annealing temperature: 45.3 °C for RANKL, 47.9 °C for OPG,
56 °C for M-CSF, and 58 °C for b-actin). Linear amplification
range for each gene was tested on the adjusted cDNA. The less
expressed transcripts of RANKL and OPG required 35 cycles of
PCR for detection. For M-CSF and b-actin, 30 and 25 cycles of
PCR was performed, respectively. The PCR samples were
electrophoresed on 1 % agarose gels in TAE buffer (0.04 M Tris-
acetate, 0.001 M EDTA). The gels were stained with ethidium
bromide (10 mg ml_1) and photographed on top of a 280 nm UV
light box. The quantity and base pair size of the PCR-generated
DNA fragments were estimated relative to DNA ladder
standards. Densitometry values were measured at each cycle
sampling using the TINA software (University of Manchester,
UK). RT-PCR values are presented as a ratio of the specified
gene’s signal in the selected linear amplification cycle divided by
the b-actin signal.
Western blot
Protein extracts were prepared from osteoblastic cells as follows.
Osteoblastic cells were resuspended in pre-warmed cracking
buffer (80 mM urea, 0.05 % SDS, 0.4 % 10 mM Tris-HCl, 1 mM
EDTA, 40 mg ml_1 bromophenol blue, 10 ml ml_1 b-mercapto-
ethanol, 70 ml ml_1 protease inhibitor cocktail (Sigma P8340)
and 50 ml 100 w PMSF (100 mM), at 60 °C), and transferred to a
tube containing glass beads (425–600 mm; Sigma). After
disruption with glass beads, the cell re-suspensions  were lysed by
heating at 70 °C for 10 min followed by vigorous vortexing for
1 min. The lysates were separated from unbroken cells by
centrifugation at 13 400 g for 5 min. For Western blot, the
protein extracts were separated by SDS–polyacrylamide gel
electrophoresis (SDS-PAGE) and transferred to a polyvinylidene
difluoride membrane (PVDF, Bio-Rad). The membrane was
incubated in a blocking solution containing 4 % bovine serum
albumin (BSA) and 10 % normal goat serum (NGS) in
phosphate-buffered saline containing 0.15 % of Tween-20
(PBS-T) at room temperature for 2 h. The blot was then probed
with the monoclonal antibody of p-JNK or t-JNK (Clontech) as
primary antibody overnight at 4 °C, and detected with
horseradish peroxidase-linked goat anti-mouse IgG antibody
(Jackson ImmunoResearch Laboratories) and an enhanced
chemiluminescence (ECL) system (Amersham Pharmacia
Biotech). This Western blot analysis was repeated four times.
ELISA
Quantikine M Mouse RANK ligand immunoassay kit (R & D
systems Inc., Minneapolis, IN, USA) was used to analyse RANKL
expression. Briefly, mRANKL was diluted in calibrator diluent
RD6-12 solution to make final concentrations of 0, 31.2, 62.5,
125, 250, 500, 1000, and 2000 pg ml_1. Assay diluent RD1W and
standards (50 ml each) were added to each well and incubated for
2 h at room temperature. A plate was provided to record
standards and samples assayed. Each well was aspirated and
washed, repeating the process four times for a total of five
washes. Mouse RANKL conjugate (100 ml) was added to each
well and incubated for 2 h at room temperature. Aspiration/
washing was repeated as described above. Substrate solution
(100 ml) was added to each well and incubated for 30 min at
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Figure 1
Inhibition of osteoclast differentiation by
bumetanide. Bumetanide was added to
osteoblast/bone marrow co-culture with
1a,25(OH)2D3. After incubation for 4 days, cells were
stained using the TRAP staining method and TRAP-
positive multinucleated cells that had more than
three nuclei were counted. A, tartrate-resistant acid
phosphatase (TRAP) staining of osteoclasts.
Osteoblast/bone marrow co-culture was treated with
10 nM 1a,25(OH)2D3 and/or 10 mM bumetanide
(Bumet). Culture conditions were described in
Methods. B, the number of TRAP-positive
multinucleated cells was decreased by bumetanide.
* Significant difference from the 1a,25(OH)2D3-
treated level (P < 0.05). C, bumetanide did not affect
the viability of the co-cultured cells up to 100 mM
concentration. The statistical significances of
differences between the groups were determined
using Kruskal-Wallis and Bonferroni tests. Data are
shown as means ± S.E.M.






























room temperature in the dark. Stop solution (100 ml) was added
to each well and mixed by gentle tapping. The optical density of
each well was determined within 30 min, using a microplate
reader at 450 nm.
Data analysis and statistics
The results are expressed as the mean ± S.E.M. The statistical
significances of differences between the groups were determined
using the Kruskal-Wallis and Bonferroni test. In statistical tests,
the P value < 0.05 was considered to be significant.
RESULTS
Bumetanide inhibits 1a,25(OH)2D3-induced osteoclast
formation
Osteoclastogenesis was induced by 1a,25(OH)2D3 in
osteoblastic cells/bone marrow co-culture. To inhibit
NKCC1 in osteoblasts, 1, 10, or 100 mM of bumetanide
was added to co-cultures and incubated at 37 °C for
4 days to investigate osteoclast differentiation. When
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Figure 2
Effect of bumetanide on mRNA expressions of RANKL, OPG and M-CSF in osteoblastic cells. Various
concentrations of bumetanide (Bumet) were added to the osteoblast culture with 10 nM 1a,25(OH)2D3.
After incubation for 4 days, total RNA was isolated. A, expression profile of mRNAs (left panel) and
densitometry of RANKL expression (right panel) in osteoblastic cells. B, ratio of RANKL and OPG
mRNA expression. RNAs were amplified according to the method described in Methods. Relative ratio
of RANKL and OPG was calculated based on the density of each band and expressed as mean ± S.E.M.
C, ELISA of RANKL expression. Quantikine M Mouse RANK ligand kit was used to analyse RANKL
expression. The assay was carried out according to the manufacturer’s instructions. * Significant






























10 nM 1a,25(OH)2D3 was added to the co-culture, 111 ± 4.2
TRAP-positive multinucleated cells were formed, whereas
no TRAP-positive cells were detected in media only. In the
presence of bumetanide (10 mM), 1a,25(OH)2D3-induced
osteoclast differentiation was reduced (Fig. 1A). The
addition of 1, 10 or 100 mM bumetanide reduced the
number of TRAP-positive multinucleated cells to 34 ± 6.8,
29 ± 5.1, or 23 ± 6.8 cells per well, respectively (Fig. 1B).
However, it might be possible that bumetanide causes cell
damage directly without interrupting the normal
maturation of osteoclasts. To investigate this possibility we
used a viability test. As shown in Fig. 1C, bumetanide did
not show a toxic effect when treated at up to 100 mM. These
results suggest that the effect of bumetanide on
differentiation was caused by a change in the NKCC1
activity, not by its direct toxic effect upon the cells.
NKCC1 inhibition caused changes in RANKL and OPG
mRNA expression during osteoclastogenesis
As shown in Fig. 2, the expressions of RANKL, OPG and
M-CSF in osteoblasts were monitored by RT-PCR in the
presence and absence of bumetanide. As the bumetanide
concentrations in the cell culture medium were increased,
the 1a,25(OH)2D3-induced expression of RANKL mRNA
was down-regulated (Fig. 2A). RANKL expression in
osteoblasts was inversely proportional to bumetanide
concentration. In contrast, the expression of OPG mRNA
increased as a function of bumetanide concentration.
These findings indicate that bumetanide inhibits osteoclast
differentiation by down-regulating the expression of
RANKL mRNA and enhancing OPG mRNA expression in
osteoblasts. However, the mRNA expression of M-CSF, an
osteoclast survival factor, was unchanged throughout the
range of bumetanide concentrations (1, 10 and 100 mM)
examined. The ratio of RANKL to OPG mRNA in osteoblast
is illustrated in Fig. 2B. As the bumetanide concentration
was increased, the ratio of RANKL to OPG mRNA
decreased, which means that the inhibition of NKCC1
activity caused changes in the mRNA expression of the
signalling molecules, RANKL and OPG, which are closely
linked to osteoclastogenesis.
RANKL expression was also analysed with ELISA using
anti-RANKL antibody (Fig. 2C). The expression of RANKL
was decreased with the increase of bumetanide
concentration. In experiments here, OPG expression was
not assayed because no remarkable change in OPG mRNA
expression was observed compared to that of RANKL
expression.
Consequently, bumetanide inhibited osteoclastogenesis, and
led to altered RANKL and OPG mRNA expressions. In
addition, such changes in the expression levels of signalling
molecules were dependent on the bumetanide concentration.
Phosphorylation of JNK was suppressed by NKCC1
inhibition
We have demonstrated how the activity of NKCC1 is
linked to the RANKL mRNA expression in osteoblastic
cells. Because JNK in general is preferentially activated by
cytokines (Gravallese et al. 2001). and cellular stress and
plays a key role in regulating the activity of various trans-
criptional factors (Anning, 2002), the changes in JNK
phosphorylation in osteoblastic cells were examined to
investigate the role of NKCC1 on RANKL mRNA
expression. Osteoblastic cells were treated with bumetanide
and incubated for 60 min. Accordingly, the inhibition of
NKCC1 by bumetanide resulted in the inhibition of JNK
phosphorylation in a dose-dependent manner, while no
significant change in the total expression of JNK (t-JNK)
was observed (Fig. 3). These findings suggest that the
activity of NKCC1 in osteoblasts is closely associated with
RANKL mRNA expression via JNK phosphorylation.
DISCUSSION
It has been reported that NKCC1 is present in osteoblasts
(Whisenant et al. 1991). However, it is not known what
NKCC1 does during osteoclastogenesis. Therefore, we
hypothesized that NKCC1 might be closely involved in
osteoclastogenesis, based upon the facts that (1) NKCCl is
present in osteoblasts, (2) NKCCl is crucial to the
regulation of the cell size and volume, which acts as a signal
for various cellular functions, and (3) NKCCl affects the
development and growth of the cells such as PC12 and
NIH3T3 (Russell, 2000). In the present study, the involvement
of NKCC1 in osteoclastogenesis was investigated by
inhibiting NKCC1 activity using bumetanide. Interestingly,
we found that bumetanide inhibited the osteoclastogenesis
(by up to 65% of the control) in a co-culture system (Fig. 1).
Bumetanide inhibited 1a,25(OH)2D3-induced osteoclasto-
genesis.
Nevertheless, it could be argued that the inhibition of
osteoclastogenesis by bumetanide might be directly due to
the cell damage, and not to the physiological intervention
of bumetanide in the normal process of osteoclastogenesis.
To rule out the possibility that bumetanide causes non-
physiological cell damage, an MTT viability test was
performed. The test showed that bumetanide did not exert
any harmful effects upon the cells in this co-culture
system, which suggests that bumetanide inhibits the
formation of TRAP-positive cells, without being toxic to
the cells.
Since osteoclast differentiation is mediated by several
factors, such as RANKL, OPG and M-CSF (Fuller et al.
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Figure 3
Effect of bumetanide on the phosphorylation of JNK.
Osteoblastic cells were treated with 10 mM
bumetanide for the indicated time. Anti-phospho-
JNK or anti-JNK antibody was used as a primary






























1998; Lacey et al. 1998; Burgess et al. 1999; Kong et al.
1999), we used an osteoblast/stromal cell co-culture system
to evaluate whether alterations in NKCC1 activity affect
the mRNA expression profiles of RANKL, OPG and M-CSF.
RANKL mRNA expression, induced by 1a,25(OH)2D3,
was down-regulated upon increasing the bumetanide
concentration, and the expression of OPG mRNA
increased. In addition, the expression of RANKL was
decreased with bumetanide concentration in the process of
1a,25(OH)2D3-induced osteoclastogenesis, being consistent
with the decrease in RANKL mRNA expression. These
findings indicate that bumetanide inhibits osteoclast
differentiation by reducing the RANKL/OPG ratio. On the
basis of such findings it might be postulated that NKCC1
activity is in part associated with osteoclastogenesis, that is,
by modulating RANKL and OPG expression in osteoblasts.
As previously described, the inhibition of NKCC1 reduced
the cellular uptake of Na+, K+ and Cl_, and this results
in cellular volume change. O’Donnell et al. (1995)
demonstrated that endothelial cell volume is also
determined by the integrated activities of kinases and
phosphatases. In particular, JNK, one of the mitogen-
activated protein kinase (MAPK) families, has been
reported to be activated by hyperosmolarity and cellular
volume changes (O’Donnell et al. 1995). These findings
suggest that JNK is associated with osteoclastogenesis via
osmotic volume change. In the present study, we have
shown that bumetanide, which is widely used as a diuretic
and as a specific inhibitor of NKCC1, inhibits osteo-
clastogenesis. Therefore, we need to determine the
correlation between JNK and NKCC1 during osteoclasto-
genesis. Here, Western blot analysis of total and
phosphorylated JNK showed that bumetanide did not
affect the expression of t-JNK, which remained constant
throughout the range of bumetanide concentrations used.
However, the activated form of JNK, i.e. p-JNK, reduced as
the bumetanide concentration was increased. Understanding
the exact nature of down-regulation of osteoclastogenesis
by the inhibition of NKCC1 requires further studies at the
level of the osteoclast.
In summary, we have provided the first evidence that in
osteoblastic cells NKCC1 plays a pivotal role in 1a,25-
(OH)2D3-induced osteoclastogenesis, via the phosphory-
lation of JNK which regulates the activity of various
transcriptional factors.
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